


AMENDMENTS TO THE CLAIMS

Please amend claims 1-46 as follows:

1. (Currently Amended) A method of treating a patient suffering from or susceptible to an RSV infection, which method comprises administering to said patient an effective amount of a compound ~~Use of a compound~~ which is (a) a benzodiazepine derivative of the formula (I) or an N-oxide thereof or (b) a pharmaceutically acceptable salt thereof, ~~in the manufacture of a medicament for use in treating or preventing an RSV infection~~



wherein:

R^1 represents C_{1-6} alkyl, aryl or heteroaryl;

R^2 represents hydrogen or C_{1-6} alkyl;

each R^3 is the same or different and represents halogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, amino, mono(C_{1-6} alkyl)amino, di(C_{1-6} alkyl)amino, nitro, cyano, $-CO_2R'$, $-CONR'R''$, $-NH-CO-R'$, $-S(O)R'$, $-S(O)_2R'$, $NH-S(O)_2R'$, $-S(O)NR'R''$ or $-S(O)_2NR'R''$, wherein each R' and R'' is the same or different and represents hydrogen or C_{1-6} alkyl;

n is from 0 to 3;

R^4 represents hydrogen or C_{1-6} alkyl;

X represents $-CO-$, $-CO-NR'-$, $-S(O)-$ or $-S(O)_2-$, wherein R' is hydrogen or a C_{1-6} alkyl group; and

R^5 represents an aryl, heteroaryl or heterocyclyl group, which group is substituted by a C_{1-6} hydroxyalkyl group or a $-(C_{1-4} \text{ alkyl})-X_1-(C_{1-4} \text{ alkyl})-X_2-(C_{1-4} \text{ alkyl})$ group, wherein X_1 represents $-O-$, $-S-$ or $-NR'-$, wherein R' represents H or a C_{1-4} alkyl group and X_2 represents $-CO-$, $-SO-$ or $-SO_2-$, or R^5 represents $-A_1-Y-A_2$, wherein:


A_1 is an aryl, heteroaryl, carbocyclyl or heterocyclyl group;

Y represents a direct bond or a C₁₋₄ alkylene, -SO₂-, -CO-, -O-, -S- or -NR'- moiety, wherein R' is a C₁₋₆ alkyl group; and

A₂ is an aryl, heteroaryl, carbocyclyl or heterocyclyl group.

2. (Currently Amended) The ~~use~~ method according to claim 1, wherein R¹ is C₁₋₂ alkyl or phenyl.
3. (Currently Amended) The ~~use~~ method according to claim 1, wherein R² is hydrogen.
4. (Currently Amended) The ~~use~~ method according to claim 1 wherein R³ is halogen, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio, C₁₋₄ haloalkyl, C₁₋₄ haloalkoxy, amino, mono(C₁₋₄ alkyl)amino or di(C₁₋₄ alkyl)amino.
5. (Currently Amended) The ~~use~~ method according to claim 4, wherein R³ is fluorine, chlorine, bromine, C₁₋₂ alkyl, C₁₋₂ alkoxy, C₁₋₂ alkylthio, C₁₋₂ haloalkyl, C₁₋₂ haloalkoxy, amino, mono(C₁₋₂ alkyl)amino or di (C₁₋₂ alkyl)amino.
6. (Currently Amended) The ~~use~~ method according to claim 1 wherein R⁴ is hydrogen or C₁₋₂ alkyl.
7. (Currently Amended) The ~~use~~ method according to claim 1 wherein X is -CO- or -CO-NR'- wherein R' represents hydrogen or a C₁₋₂ alkyl group.
8. (Currently Amended) The ~~use~~ method according to claim 1, wherein R⁵ is a 5- or 6-membered heterocyclyl or heteroaryl ring which is substituted by a C₁₋₆ hydroxyalkyl group or a -(C₁₋₄ alkyl)-X₁-(C₁₋₄ alkyl)-X₂-(C₁₋₄ alkyl) group, wherein X₁ and X₂ are as defined in claim 1.
9. (Currently Amended) The ~~use~~ method according to claim 8, wherein R⁵ is a 5- or 6-membered heteroaryl group which is substituted by a -CH₂-OH or -(C₁₋₄ alkyl)-NR'-(C₁₋₄ alkyl)-S(O)₂-(C₁₋₄ alkyl) substituent, wherein R is hydrogen or C₁₋₂ alkyl.

10. (Currently Amended) The ~~use~~ method according to claim 1, wherein A₁ is an aryl or heteroaryl group.
11. (Currently Amended) The ~~use~~ method according to claim 10, wherein A₁ is a phenyl group, a monocyclic 5- or 6-membered heteroaryl group or a 5- to 6-membered heteroaryl group fused to a monocyclic oxo-substituted 5- to 6-membered heterocyclyl group.
12. (Currently Amended) The ~~use~~ method according to claim 1 wherein A₁ is unsubstituted or substituted by 1 or 2 substituents selected from halogen, cyano, nitro, C₁₋₄ alkyl, C₁₋₄ haloalkyl and C₁₋₄ alkoxy substituents.
13. (Currently Amended) The ~~use~~ method according to claim 1, wherein Y represents a direct bond, a C₁₋₂ alkylene group, -SO₂- or -O-.
14. (Currently Amended) The ~~use~~ method according to claim 1, wherein A₂ is a phenyl, 5- to 6-membered heteroaryl, 5- to 6-membered heterocyclyl or C₃₋₆ cycloalkyl group.
15. (Currently Amended) The ~~use~~ method according to claim 1, wherein when A₂ is a heterocyclyl group it is attached to the moiety Y via a N atom.
16. (Currently Amended) The ~~use~~ method according to claim 1, wherein A₂ is unsubstituted or is substituted by 1 or 2 substituents which are selected from C₁₋₄ alkyl and halogen substituents when A₂ is a heteroaryl or aryl group and which are selected from C₁₋₄ alkyl, halogen and oxo substituents when A₂ is a carbocyclic or heterocyclyl group.
17. (Currently Amended) The ~~use~~ method according to claim 1, wherein A₂ is a piperazinyl, pyridyl, morpholinyl, pyrrolidinyl, piperidinyl, pyrazinyl, cyclopropyl, phenyl or S,S-dioxo-thiomorpholino group, which is unsubstituted or substituted by a C₁₋₂ alkyl group.
18. (Currently Amended) The ~~use~~ method according to claim 1, wherein the benzodiazepine derivative of formula (I) is a benzodiazepine derivative of formula (Ia):



wherein:

X is -CO- or -CO-NH-; and

R⁵ is a 5- to 6- membered heteroaryl group, for example a furanyl group, which is substituted by -CH₂-OH or -(C₁₋₄ alkyl)-N(CH₃)-(C₁₋₄ alkyl)-SO₂-(C₁₋₄ alkyl) or R⁵ represents – A₁-Y-A₂, wherein: A₁ is a phenyl, pyridyl, furanyl, thiazolyl, oxazolyl, isoxazolyl, thienyl or 1H-imidazo[4,5-b]pyridin-2-(3H)-one moiety, which is unsubstituted or substituted by 1 or 2 substituents selected from halogen, cyano, C₁₋₂ alkyl, C₁₋₂ haloalkyl and C₁₋₂ alkoxy substituents;

Y is a direct bond, a C₁₋₂ alkylene group, -SO₂- or -O- ; and

A₂ is a piperazinyl, pyridyl, morpholinyl, pyrrolidinyl, piperidinyl, pyrazinyl, cyclopropyl, phenyl or S,S-dioxo-thiomorpholino group, which is unsubstituted or substituted by a C₁₋₂ alkyl group.

19. (Currently Amended) The ~~use~~ method according to claim 1, wherein the medicament is for use in treating a patient who is a child under two years of age, an adult suffering from asthma, chronic obstructive pulmonary disorder (COPD) or immunodeficiency, an elderly person or a person in a long term care facility.

20. (Currently Amended) The ~~use~~ method according to claim 19 wherein said child suffers from chronic lung disease.

21. (Currently Amended) The ~~use~~ method according to claim 1 wherein the medicament is for use in preventing RSV infection in an infant less than six years of age who was born after 32 weeks of gestation or less.

22. (Currently Amended) The ~~use~~ method according to claim 1, wherein the medicament is suitable for intranasal or intrabronchial administration.

23. (Currently Amended) The ~~use~~ method according to claim 1, wherein the medicament further comprises an anti-inflammatory compound or an anti-influenza compound.
24. (Currently Amended) The ~~use~~ method according to claim 23 wherein the anti-inflammatory compound is budesonide or fluticasone.
25. (Currently Amended) The ~~use~~ method according to claim 23 wherein the anti-inflammatory compound is a leukotriene antagonist, phosphodiesterase 4 inhibitor or TNF alpha inhibitor.
26. (Currently Amended) The ~~use~~ method according to claim 23 wherein the anti-inflammatory compound is an interleukin 8 or interleukin 9 inhibitor.
27. (Currently Amended) The ~~use~~ method according to claim 1 wherein the medicament is coadministered with an anti-inflammatory compound, wherein the anti-inflammatory compound is selected from the group consisting of budesonide, fluticasone, a leukotriene antagonist, phosphodiesterase 4 inhibitor, TNF alpha inhibitor, an interleukin 8 inhibitor and an interleukin 9 inhibitor.
28. (Canceled)
29. (Currently Amended) The ~~[[A]]~~ method according to claim 1 ~~claim 28~~, wherein said patient is selected from the group consisting of a child under two years of age, an adult suffering from asthma, chronic obstructive pulmonary disorder (COPD) or immunodeficiency, an elderly person, a person in a long term care facility, a child under two years of age that suffers from chronic lung disease, and an infant less than six years of age who was born after 32 weeks of gestation or less.
30. (Currently Amended) The ~~[[A]]~~ method according to claim 29 ~~claim 28~~, wherein said compound is administered intranasally or intrabronchially.
31. (Withdrawn) An inhaler or nebuliser containing a medicament which comprises


- (a) a compound as defined in claim 1, and
- (b) a pharmaceutically acceptable carrier or diluent.

32. (Withdrawn) A product comprising a compound as defined in claim 1 and an anti-inflammatory compound selected from the group consisting of budesonide, fluticasone, a leukotriene antagonist, a phosphodiesterase 4 inhibitor, a TNF alpha inhibitor, an interleukin 8 inhibitor and an interleukin 9 inhibitor, or an anti-influenza compound.

33. (Currently Amended) The method of claim 1, wherein the patient suffers from ~~The use of a product according to claim 32 in the manufacture of a medicament for use in the treatment of concomitant RSV and influenza infections.~~

34. (Currently Amended) The method of claim 1, wherein the patient suffers from ~~The use of a compound as defined in claim 1 in the manufacture of a medicament for use in the treatment of human metapneumo virus, measles, parainfluenza viruses, mumps, yellow fever virus (B5 strain), Dengue 2 virus or West Nile virus.~~

35. (Withdrawn) A compound which is (a) a benzodiazepine derivative of formula (Ib) or an N-oxide thereof, or (b) a pharmaceutically acceptable salt thereof



wherein R₁, R₃, n, R₄, X and R₅ are as defined in claim 1.

36. (Withdrawn) A compound according to claim 35, wherein R₁ is an unsubstituted phenyl group.

37. (Withdrawn) A compound according to claim 35, wherein when A₁ is a heteroaryl group, it is other than a 5-methyl-isoxazolyl moiety.

38. (Withdrawn) A compound according to claim 1, wherein A₁ is an aryl or heteroaryl moiety.

39. (Withdrawn) A compound according to claim 1, wherein X is -CO- or -CO-NR'-, wherein R' is as defined in claim 1, provided that when X is -CO-NR'-, the moiety -A₁-Y-A₂ is -phenyl-O-phenyl.

40. (Withdrawn) A compound according to claim 1, wherein A₂ is other than a 4- to 10-membered saturated cycloalkyl ring, in which one of the carbon atoms is replaced by a N atom.

41. (Withdrawn) A compound according to claim 1, wherein A₂ is a piperazinyl, pyridyl, pyrrolidinyl, pyrazinyl, cyclopropyl, phenyl or S,S-dioxo- thiomorpholino group which is unsubstituted or is substituted by a C₁₋₂ alkyl group.

42. (Withdrawn) A compound according to claim 35, wherein the benzodiazepine derivative of the formula (Ib) is:

6-(4-Methyl-piperazin-1-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-nicotinamide;

3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-5'-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2-Chloro-4-morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2-(1, 1-Dioxo-1λ6-thiomorpholin-4-yl)-4-fluoro-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-5-Chloro-2-(1, 1-dioxo-1λ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-5-fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-5-(4-Methyl-piperazin-1-ylmethyl)-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-5-Pyrrolidin-1-ylmethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-5-Piperidin-1-ylmethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-5-Dimethylaminomethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-4-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-piperidin-1-yl-benzamide;

(S)-4-Fluoro-2-morpholino-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-4-Cyano-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-pyrrolidin-1-yl-benzamide;

(S)-4-Cyano-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-piperidine-1-yl-benzamide;

(S)-N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-pyrrolidin-1-yl-4-trifluoromethyl-benzamide;

(S)-N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-piperidin-1-yl-4-trifluoromethyl-benzamide;

(S)-2-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-4-trifluoromethyl-benzamide;

(S)-N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-pyrrolidin-1-yl-5-trifluoromethyl-benzamide;

(S)-2-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-5-trifluoromethyl-benzamide;

(S)-2-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide;

(S)-2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide;

(S)-2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-3-methyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-4-methyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-6-methyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2-Chloro-6-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-3-Cyclopropyl-2-oxo-2,3-dihydro-imidazo[4,5-b]pyridine-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-3-(4-Methyl-piperazine-1-sulfonyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-4-(4-Methyl-piperazin-1-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(piperidine-1-sulfonyl)-benzamide;

(S)-3-(Morpholine-4-sulfonyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-5-Morpholin-4-ylmethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-5-Hydroxymethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-5-(1,1-Dioxo-1λ6-thiomorpholin-4-ylmethyl)-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-2-Chloro-4-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2-Chloro-5-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-5-([(2-Methanesulfonyl-ethyl)-methyl-amino]-methyl)-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-2-Pyridin-3-yl-thiazole-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-2-Pyridin-4-yl-thiazole-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-4-Methyl-2-pyrazin-2-yl-thiazole-5-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-2-Morpholin-4-ylmethyl-furan-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-3-Morpholin-4-ylmethyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-benzamide;

(S)-5-Morpholin-4-ylmethyl-isoxazole-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-3-Morpholin-4-ylmethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-5-Pyridin-2-yl-thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-2-Methyl-4-(morpholin-4-sulfonyl)-furan-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-6-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide;

(S)-3-Morpholin-4-ylmethyl-thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-5-Morpholin-4-ylmethyl-thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

2-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-5-Phenyl-oxazole-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide; or

1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(4-phenoxy-phenyl)-urea.

43. (Withdrawn) A compound according to claim 35 for use in a method of treating the human or animal body.

44. (Withdrawn) A pharmaceutical composition comprising a compound according to claim 35, and a pharmaceutically acceptable diluant or carrier.

45. (Withdrawn) A composition according to claim 44 comprising an optically active isomer of a compound according to claim 35.
46. (Withdrawn) A composition according to claim 44 which is in the form of a tablet, troche, lozenge, aqueous or oily suspension, dispersible powders or granules.
47. (New) A method of according to claim 1, wherein the compound is (S)-4-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-piperidin-1-yl-benzamide; (S)-4-Fluoro-2-morpholino-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-benzamide; or (S)-2-Chloro-4-morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-benzamide.